<DOC>
	<DOCNO>NCT01666652</DOCNO>
	<brief_summary>The study design afford first time human ( FTiH ) safety immunogenicity assessment three Tetravalent Dengue Virus-Purified Inactivated Vaccine ( TDENV-PIV ) vaccine candidate , formulate different adjuvant : either aluminum hydroxide , AS01E AS03B ( adjuvant use Glaxo Smith Kline ( GSK ) Biologicals ' hepatitis B candidate vaccine , malaria candidate vaccine pandemic flu vaccine , respectively ) . Each vaccine candidate contain 1 µg purify virus antigen per four DENV type . Additionally , study evaluate alum adjuvanted TDENV-PIV vaccine candidate contain 4 µg purify virus antigen per four DENV type . The control group receive saline placebo . All experimental vaccination administer accord 2-dose schedule , 28 day apart .</brief_summary>
	<brief_title>A Two-dose Primary Vaccination Study Tetravalent Dengue Virus Purified Inactivated Vaccine v . Placebo Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Aluminum sulfate</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol ( e.g. , completion diary card , return followup visit , etc . ) A male female 18 39 year age ( inclusive ) time consent Written inform consent obtain subject Healthy subject establish medical history clinical examination enter study Female subject nonchildbearing potential ( nonchildbearing potential define either current tubal ligation least three month prior enrollment , hysterectomy , ovariectomy , postmenopause ) . See Definition Terms adequate contraception . Female subject childbearing potential may enrol study , subject : Practiced adequate contraception 30 day prior vaccination , A negative urine pregnancy test day vaccination , Agreed continue adequate contraception two month completion vaccination series Use investigational nonregistered product ( drug vaccine ) study vaccines/placebo period start 30 day precede first dose study vaccine/placebo and/or plan use study period Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug period start 180 day prior first vaccine/placebo dose ( corticosteroid , mean prednisone ≥ 20 mg/day equivalent ; inhale topical steroid allow ) Planned administration administration vaccine/product foreseen study protocol period start 30 day prior first dose vaccine/placebo visit Day 56 ( influenza activity warrant vaccination healthy young adult , influenza vaccination encourage lead study exclusion ) Planned administration flavivirus vaccine entire study duration Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Any confirm suspect immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Family history congenital hereditary immunodeficiency History , current autoimmune disease History reaction hypersensitivity likely exacerbate component vaccine/placebo relate study procedure Major congenital defect serious chronic illness History neurological disorder seizures Acute disease and/or fever ( ≥37.5°C/99.5°F oral body temperature ) time enrollment ( subject minor illness , i.e. , mild diarrhea , mild upper respiratory infection , etc. , without fever , may enrol discretion investigator ) Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test Administration immunoglobulins and/or blood product period start 90 day precede first dose study vaccine/placebo plan administration study period History chronic alcohol consumption and/or drug abuse Pregnant lactate female female planning become pregnant planning discontinue contraceptive precaution A plan move location prohibit participate trial study end participant Any condition , opinion investigator , prevents subject participate study . Subject seropositive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) , human immunodeficiency virus antibody ( antiHIV ) Safety laboratory test result outside acceptable value screen . The follow value acceptable : &gt; 110 % upper limit normal ( ULN ) alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase , creatinine , serum urea nitrogen ( SUN ) bilirubin ( total direct ) &lt; 100 % low limit normal ( LLN ) &gt; 120 % ULN hemoglobin , hematocrit platelet count &lt; 75 % LLN &gt; 110 % ULN total white blood cell count ( WBC ) Note screen laboratory result must either within normal limit ( WNL ) Grade l clinically significant ( NCS ) ( LLN=lower limit normal ; ULN= upper limit normal , WNL= within normal limit , NCS= clinically significant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Dengue</keyword>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>Flavivirus</keyword>
</DOC>